http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2022195414-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d64d78e8540b2b8546a76676ac488243 |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5156 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-03 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0636 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0645 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0093 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0087 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N13-00 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N13-00 |
filingDate | 2020-03-24^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3ce0e2efc9350c28c887f7fe2b07449a |
publicationDate | 2022-06-23^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | US-2022195414-A1 |
titleOfInvention | Improved Manufacturing Procedures for Cell Based Therapies |
abstract | CAR T cell therapies have shown promise in treating human blood cell cancer. The preparation of CAR T cells involves many complex, time consuming steps prior to infusion of the CAR T cells into a cancer patient. One step in the process to create CAR T cells often involves using magnetic separation technologies to isolate specific subsets of T cells prior to creating the CAR T cells. When using current magnetic separation technologies to remove undesired cell populations the recovery of the desired cell population can be as low as 50-70% or even lower and the procedures often take 30-60 minutes. In the case of autologous CAR T cell therapies such cell loss is often not acceptable. The present invention offers means to improve the recovery of desired cells to close to 100% very rapidly thus significantly improving a step in the manufacture of CART cells and in many cases will make such therapy possible for a larger patient population. |
priorityDate | 2019-04-08^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 37 of 37.